# Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects

> **NCT02045966** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 16 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Cocktail
- **DRUG:** DCV 3DAA FDC
- **DRUG:** BMS-791325

## Key facts

- **NCT ID:** NCT02045966
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02045966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02045966, "Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02045966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*